Medical news of Remedium.ru portal is the most update information on pharmaceutical and medical equipment market

Journals

REMEDIUM

The periodical about the pharmaceutical and medical equipment markets

ROSSIYSKIE APTEKI

(Russian pharmacies) - specialized periodical edition for pgarmacy professionals

MEDITSINSKY SOVET

Medical Council - Scientific Journal for Physicians


Home / News

17.08.2011

Russian firms set up $113 million biotech venture

Several Russian companies have linked up to establish a joint venture designed to develop innovative treatments in the country.

The SynBio project has been initiated by the Human Stem Cells Institute (HSCI), Russia's leading biotechnology company, which will have a 28.1% stake in the venture. It has attracted investment from the government-owned investment company Rusnano, which will have a 41.4% holding and other Russian firms involved include Cryonix and Pharmsynthez.

The lead R&D partner for the project is the UK's Lipoxen, which is in the process of merging with Germany's SymbioTec. SynBio will focus on developing treatments based on three technological platforms, ie it will look at drugs engineered from cell-based technologies for the treatment of chronic diffuse liver disease, plus treatments based on the human nuclear protein histone H1 for cancer and other diseases.
Related Links
Pfizer signs drug pact with Russia s ChemRar AstraZeneca ups investment in Russia Russians overestimate their state of health study

Thirdly, SynBio will focus on "sustained-release drugs using polysialic acid", ie 'biobetters' for the treatment of diabetes, Alzheimer's, chronic kidney disease and a number of other conditions. The total budget for the project over the next four years amounts to around 3.22 billion roubles, roughly $113 million.

HSCI general director Artur Isaev said "it is difficult to overstate the importance" of the JV because "for the first time a Russian company is acting as the initiator of an international M&A project in the biotech sector to serve both the Russian and global markets". He added that Synbio is "an excellent example of how the government’s programme for innovative development of the Russian pharmaceutical sector can be implemented".

Source:  www.pharmatimes.com

Remedium group

REMEDIUM

publishing house

CLIFAR

programmer of electronic software products

R-PRESS

advertisement agency

REPRENT

rent-a-rep company